Bayer Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAYER, and when can generic versions of BAYER drugs launch?
BAYER has one hundred and twenty-four approved drugs.
There are fifty-four US patents protecting BAYER drugs. There is one tentative approval on BAYER drugs.
There are one thousand one hundred and three patent family members on BAYER drugs in sixty countries and one hundred and ninety-eight supplementary protection certificates in twenty countries.
Summary for Bayer
| International Patents: | 1103 |
| US Patents: | 54 |
| Tradenames: | 109 |
| Ingredients: | 73 |
| NDAs: | 124 |
| Patent Litigation for Bayer: | See patent lawsuits for Bayer |
Drugs and US Patents for Bayer
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | LEVITRA | vardenafil hydrochloride | TABLET;ORAL | 021400-001 | Aug 19, 2003 | DISCN | Yes | No | 8,273,876 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bayer Pharms | VI-DOM-A | vitamin a palmitate | CAPSULE;ORAL | 080972-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bayer Pharms | STILPHOSTROL | diethylstilbestrol diphosphate | TABLET;ORAL | 010010-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bayer Pharms | MEZLIN | mezlocillin sodium monohydrate | INJECTABLE;INJECTION | 062697-001 | Jan 22, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bayer Healthcare Llc | CLARITIN | loratadine | CAPSULE;ORAL | 021952-001 | Jun 16, 2008 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bayer Hlthcare | MAGNEVIST | gadopentetate dimeglumine | INJECTABLE;INJECTION | 019596-001 | Jun 2, 1988 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-002 | Nov 26, 2018 | RX | Yes | Yes | 8,513,263 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Bayer
Paragraph IV (Patent) Challenges for BAYER drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 40 mg | ➤ Subscribe | 2016-09-27 |
| ➤ Subscribe | Oral Suspension | 250 mg/5 mL and 500 mg/ 5 mL | ➤ Subscribe | 2009-10-16 |
| ➤ Subscribe | Tablets | 3 mg/0.03 mg | ➤ Subscribe | 2005-01-07 |
| ➤ Subscribe | Orally Disintegrating Tablets | 10 mg | ➤ Subscribe | 2011-12-22 |
| ➤ Subscribe | Tablets | 0.5 mg/1 mg | ➤ Subscribe | 2007-12-26 |
| ➤ Subscribe | Tablets | 3 mg/0.02 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2011-11-21 |
| ➤ Subscribe | Tablets | 20 mg | ➤ Subscribe | 2009-03-05 |
| ➤ Subscribe | Tablets | 2.5 mg | ➤ Subscribe | 2009-09-04 |
| ➤ Subscribe | Tablets | 200 mg | ➤ Subscribe | 2014-02-28 |
| ➤ Subscribe | Tablets | 3 mg/0.03 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2012-09-28 |
| ➤ Subscribe | Transdermal System | 0.05 mg/day and 0.1 mg/day | ➤ Subscribe | 2005-09-12 |
| ➤ Subscribe | Tablets | 3 mg/0.02 mg | ➤ Subscribe | 2006-09-29 |
| ➤ Subscribe | Injection | 1.6 mg/mL | ➤ Subscribe | 2014-02-07 |
| ➤ Subscribe | Tablets | 0.5 mg, 1 mg,1.5 mg, 2 mg and2.5 mg | ➤ Subscribe | 2017-10-10 |
| ➤ Subscribe | Tablets | 0.25 mg/0.5 mg | ➤ Subscribe | 2015-01-08 |
| ➤ Subscribe | Tablets | 3 mg/0.02 mg/0.451 mg and 0.451 mg | ➤ Subscribe | 2012-11-13 |
| ➤ Subscribe | Tablets | 5 mg ad 10 mg | ➤ Subscribe | 2009-07-10 |
| ➤ Subscribe | Tablets | 3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mg | ➤ Subscribe | 2010-10-22 |
| ➤ Subscribe | Tablets | 25 mg, 50 mg and 100 mg | ➤ Subscribe | 2005-03-22 |
International Patents for Bayer Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2009511526 | ⤷ Try a Trial |
| Russian Federation | 2581585 | ⤷ Try a Trial |
| Brazil | 112013025549 | ⤷ Try a Trial |
| Hong Kong | 1114605 | ⤷ Try a Trial |
| Japan | 2006528196 | ⤷ Try a Trial |
| Norway | 20052076 | ⤷ Try a Trial |
| China | 101098714 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bayer Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0770388 | 9/2009 | Austria | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION AUS ESTRADIOLVALERAT UND DIENOGEST; NAT. REGISTRATION NO/DATE: 1-28003 20090203; FIRST REGISTRATION: BE BE 327792 20081103 |
| 3106463 | 122020000012 | Germany | ⤷ Try a Trial | PRODUCT NAME: LAROTRECTINIB ODER ANDERE PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, EINSCHLIESSLICH LAROTRECTINIBSULFATE UMFASSEND LAROTRECTINIBHYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/19/1385 20190919 |
| 1506193 | 515 | Finland | ⤷ Try a Trial | |
| 2493858 | 132020000000064 | Italy | ⤷ Try a Trial | PRODUCT NAME: DAROLUTAMIDE(NUBEQA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1432, 20200330 |
| 1506193 | 2014/028 | Ireland | ⤷ Try a Trial | PRODUCT NAME: RIOCIGUAT OR A SALT, ISOMER OR HYDRATE THEREOF; REGISTRATION NO/DATE: EU/1/13/907/001-015 20140327 |
| 2493858 | C202030032 | Spain | ⤷ Try a Trial | PRODUCT NAME: DAROLUTAMIDA, OPCIONALMENTE EN FORMA DE SAL O ESTER FARMACEUTICAMENTE ACEPTABLE; NATIONAL AUTHORISATION NUMBER: EU/1/20/1432; DATE OF AUTHORISATION: 20200327; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1432; DATE OF FIRST AUTHORISATION IN EEA: 20200327 |
| 1663978 | C 2014 007 | Romania | ⤷ Try a Trial | PRODUCT NAME: REGORAFENIB SI SARURILE SALE4-[4-({[4-CLORO-3-(TRIFLUOROMETIL)-FENIL]CARBAMOIL}AMINO)-TIONAL AUTHORISATION: 20130826; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/858; DATE OF FIRST AUTHORISATION IN EEA: 20130826 3-FLUOROFENOXI]-N-METILPIRIDIN-2-CARBOXAMIDA; NATIONAL AUTHORISATION NUMBER: EU/1/13/858; DATE OF NA |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
